ClinicalTrials.gg
CompletedNCT03928704BE MOBILE 1Updated Sep 25, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

A Phase 3 interventional study of Bimekizumab and Placebo in Nonradiographic Axial Spondyloarthritis, sponsored by UCB Biopharma SRL. Completed at 83 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
274
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Axial Spondyloarthritis by UCB S.A. — 2 open to participants now, 2 under way, none of them phase 3. Axial Spondyloarthritis · UCB S.A..

Enrollment
6th of 11
274 · median 274
Started
2019
with 1 other
Phase 3
5 of 13
none open now
Registered
8th of 13
by date

Among the 13 studies in Axial Spondyloarthritis by UCB S.A., this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2019, is one of 5 in phase 3, and was the 8th registered.

Axial Spondyloarthritis

186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

2 of the 13 studies in Axial Spondyloarthritis by UCB S.A. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Axial Spondyloarthritis by UCB S.A., or all of them as a file.
02

Study summary

The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis (nr-axSpA).

03

Conditions studied

  • Nonradiographic Axial Spondyloarthritis

Keywords

  • Nonradiographic axial spondyloarthritis
  • Axial spondyloarthritis
  • Nr-axSpA
  • Bimekizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients at least 18 years of age
  • Patient has nonradiographic axial spondyloarthritis (nr-axSpA) with all of the following criteria:

    1. Adult-onset axial spondyloarthritis meeting Assessment of SpondyloArthritis International Society (ASAS) classification criteria
    2. Inflammatory back pain for at least 3 months
    3. Age at symptom onset of less than 45 years
    4. NO sacroiliitis (in Anterior-Posterior pelvis or sacroiliac x-ray)
  • Active disease defined by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) >=4 AND spinal pain >=4 on a 0 to 10 Numeric Rating Scale
  • Objective inflammation defined by sacroiliitis on magnetic resonance imaging and/or elevated C-reactive protein
  • Subjects had to have either failed to respond to 2 different nonsteroidal anti-inflammatory drugs (NSAIDs) given at the maximum tolerated dose for a total of 4 weeks or have a history of intolerance to or a to NSAID therapy
  • Patients who have taken a tumor necrosis factor alpha (TNFα) inhibitor must have experienced an inadequate response or intolerance to treatment given at an approved dose for at least 12 weeks
  • Patients currently taking NSAIDs, cyclooxygenase 2 (COX-2) inhibitors, analgesics, , methotrexate (MTX), leflunomide (LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ) AND/OR apremilast can be allowed if they fulfill specific requirements prior to study entry

Exclusion criteria

Exclusion Criteria:

  • Treatment with more than 1 TNFα inhibitor and/or more than 2 additional non-TNFα biological response modifiers, or any interleukin (IL)-17 biological response modifier
  • Active infection or history of recent serious infections
  • Viral or C or (HIV) infection
  • Any live (includes attenuated) vaccination within the 8 weeks prior to entering the study or TB (Bacillus Calmette-Guerin) vaccination within 1 year prior entering the study
  • Known tuberculosis (TB) infection, at high risk of acquiring TB infection, or current or history of nontuberculous mycobacterium (NTMB) infection
  • Subject has any active or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma or in situ cervical cancer
  • Diagnosis of inflammatory conditions other than axial spondyloarthritis (axSpA), including but not limited to psoriatic arthritis, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus, and reactive arthritis. Patients with a diagnosis of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease (IBD) are allowed as long as they have no active symptomatic disease when entering the study
  • Presence of active suicidal ideation, or moderately severe major depression or severe major depression
  • Female patients who are breastfeeding, pregnant, or planning to become pregnant during the study
  • Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
274 participants (actual)

Study arms

  • Experimental
    Bimekizumab

    Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.

    Drug: Bimekizumab

  • Placebo comparator
    Placebo

    Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.

    Drug: Bimekizumab · Other: Placebo

Interventions

  • Subjects will receive bimekizumab at pre-specified time-points.

    Also known as: BKZ, UCB4940

  • OtherPlacebo

    Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16

    ASAS40 response is defined as relative improvements of at least 40% and absolute improvement of at least 2 units in at least 3 of the 4 following components:1) Patient's Global Assessment of Disease Activity (PGADA) assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most severe pain\], higher score= higher pain intensity, 3) Bath Ankylosing Spondylitis Functional Index (BASFI) assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), each assessed on a scale ranging from 0 \[none / 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity; and no worsening at all in the remaining component.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Subjects at Week 16

    ASAS40 response is defined as relative improvements of at least 40% and absolute improvement of at least 2 units in at least 3 of the 4 following components:1) Patient's Global Assessment of Disease Activity (PGADA) assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most severe pain\], higher score= higher pain intensity, 3) Bath Ankylosing Spondylitis Functional Index (BASFI) assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), each assessed on a scale ranging from 0 \[none / 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity; and no worsening at all in the remaining component.

    Time frame: Week 16

  2. Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16

    BASDAI is a well-established patient-reported endpoint assessing severity of AS symptoms. It is made of 6 items assessing severity of fatigue, spinal pain, peripheral joint pain \& swelling, enthesitis, \& morning stiffness (both severity and duration). Each question is rated using a numerical rating scale ranging from 0 (none) to 10 (very severe), higher score=higher symptom severity.BASDAI score is calculated by computing mean of questions 5 and 6 \& adding it to sum of questions 1 to 4.This score is then divided by 5.Total BASDAI score ranges from 0=no disease activity to 10=maximal disease activity, higher score indicates higher symptom severity. A negative change reflects improvement.

    Time frame: Baseline, Week 16

  3. Percentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 16

    ASAS20 response is defined as relative improvements of at least 20% and absolute improvement of at least 1 unit in at least 3 of the 4 following components:1) PGADA assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most severe pain\], higher score= higher pain intensity, 3) BASFI assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities, 4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI, each assessed on a scale ranging from 0 \[none / 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity; and no worsening at all in the remaining component.

    Time frame: Week 16

  4. Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 16

    The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of less than or equal to (\<=) 2 units in each of the 4 following components:1) PGADA assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity,2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most severe pain\], higher score= higher pain intensity, 3) BASFI assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities, and 4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI scale, each assessed on a scale ranging from 0 \[none / 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity.

    Time frame: Week 16

  5. Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 16

    ASDAS-MI is achieved when there is a reduction (improvement) greater or equal to (\>=) 2.0 in ASDAS relative to Baseline. ASDAS is calculated by adding the 5 following components: 1) 0.121 × Neck, back or hip pain (BASDAI Q2), 2) 0.058 × Duration of morning stiffness (BASDAI Q6), 3) 0.110 × Patient's Global Assessment of Disease Activity (PGADA), 4) 0.073 × Peripheral pain/swelling in joints (BASDAI Q3), 5) 0.579 × (natural logarithm of the C-reactive protein (CRP) \[mg/L\] + 1). Q2, Q3 and Q6 from BASDAI and PGADA, are all assessed on a numerical scale from 0 \[none / not active\] to 10 \[very severe / very active\]. There is a minimum score of 0.980 for ASDAS (as a fixed value of 2 is assumed for values of hs-CRP below the lower limit of quantification (LLOQ)), but no defined upper score. Higher ASDAS scores reflect higher disease activity and participants achieving ASDAS-MI are considered to have a major improvement in their disease.

    Time frame: Week 16

  6. Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 16

    ASAS 5/6 response is defined as achieving at least 20% improvement in 5 of the following 6 components:1) PGADA assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most intense pain\], higher score=higher pain intensity,3) BASFI assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI scale, each assessed on a scale ranging from 0 \[none/ 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity;5) spinal mobility (ie, lateral spinal flexion component of Bath Ankylosing Spondylitis Disease Metrology Index) on a scale ranging from 0 \[no limitation of movement\] to 10 \[very severe limitation of movement\] and 6) high sensitivity C-reactive protein (hs-CRP).

    Time frame: Week 16

  7. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16

    The BASFI is a well-established PRO measure of physical functioning used in AxSpA trials. It assesses participants' level of ability during the past week in conducting 10 physical activities on a scale ranging from 0 \[easy\] to 10 \[impossible\]. The BASFI score is the mean of the 10 item scores and ranges from 0 to 10, with lower scores indicating better physical function. A negative change in BASFI indicates improvement. The higher the negative value the better the improvement.

    Time frame: Baseline, Week 16

  8. Change From Baseline in Nocturnal Spinal Pain Score Using Numeric Rating Scale (NRS) at Week 16

    Nocturnal spinal pain experienced by participants with axial spondyloarthritis (axSpA) was assessed on a numerical rating scale ranging from 0 (no pain) to 10 (most severe pain). A lower score indicates less pain and a negative change represents an improvement.

    Time frame: Baseline, Week 16

  9. Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16

    The Ankylosing Spondylitis Quality of Life (ASQoL) is an 18-item PRO measure developed specifically for measuring health-related quality of life (HRQoL) in participants with ankylosing spondylitis and validated in the full spectrum of axial spondyloarthritis (axSpA). Each item is given a score of 1 for positive responses indicating impaired quality of life, and a score of 0 for negative responses. All item scores are summed to generate the total score ranging from 0 to 18 with a higher score indicating worse HRQoL. A negative change represents an improvement.

    Time frame: Baseline, Week 16

  10. Change From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 16

    SF-36 is a 36-item HRQoL instrument with recall period of 4 weeks. Items are grouped into 8 domains: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items) and 1 item for Health Transition during last year. PCS and Mental Component Summary (MCS) scores are calculated from 8 domains (excluding Health Transition item). Each of SF-36 derived raw scores range from 0 to 100; higher score = better function. PCS score is calculated from 8 domain scores. It is standardized score ranging from 7.3 to 70.1, with a mean of 50 and SD of 10 in general US population, higher values = better function, and positive change reflects improvement. A PCS score mean below 47 indicates impaired physical functioning. Individual respondent's score that falls outside T-score range of 45 to 55 are outside average general US population range.

    Time frame: Baseline, Week 16

  11. Change From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16

    The BASMI characterizes the spinal mobility of participants with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis. It is a disease-specific measure consisting of 5 clinical measures to reflect participant axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 was calculated for each item based on the measurement. The mean of the 5 scores provides the total BASMI score (ranging from 0 to 10). The higher the BASMI score, the more severe the participant's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value, the better the improvement.

    Time frame: Baseline, Week 16

  12. Change From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16

    The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score reflects higher severity and a negative change represents an improvement.

    Time frame: Baseline, Week 16

  13. Percentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline

    The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. Enthesitis free state is defined as having a MASES score of 0. A higher score reflects higher severity and a negative change represents an improvement.

    Time frame: Baseline, Week 16

  14. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

    TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety follow up (SFU)). TEAEs were analyzed and have been reported separately for Double-Blind Treatment Period (Safety set),Maintenance Period (MP) (Maintenance Set) and Overall Period (Safety set) which includes all participants who received BKZ 160 mg Q4W during the study. The overall period arm reports repeated TEAEs from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, Maintenance Period (MP) included AEs of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.

    Time frame: From Baseline (Day 1) until Safety-Follow-Up (up to Week 68) (Week 48 last IMP intake + 20 weeks SFU)

  15. Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study

    A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in 1) Death, 2) Life-threatening (Life-threatening does not include a reaction that might have caused death had it occurred in a more severe form.), 3) Significant or persistent disability/incapacity, 4) Congenital anomaly/birth defect (including that occurring in a fetus), 5) Important medical event that, based upon appropriate medical judgment, may jeopardize the participant or participant may require medical or surgical intervention to prevent any of the above, 6) Initial inpatient hospitalization or prolongation of hospitalization. The overall period arm reports repeated SAEs from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, MP included SAEs of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 68)

  16. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study

    TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). The overall period arm reports repeated events from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, MP included events of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.

    Time frame: From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)

07

Results

Posted Nov 13, 2024

Participant flow

The study started to enroll participants in April 2019 and concluded in April 2023. Among the total of 274 participants, 254 participants were enrolled under the global study protocol by June 2021, including 16 enrolled in China. The enrolment was extended in China to achieve the target of 36 participants as agreed with the local agency and additional 20 Chinese participants were enrolled by February 2022 in the China Extension population.

Double-Blind Treatment Period:Week 1-16
Participant flow — Double-Blind Treatment Period:Week 1-16
MilestonePlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population)
Started12612801190
Started chinese participants7901190
Completed11812601190
Not completed820000
Withdrew: Patient compliance010000
Withdrew: Withdrawal by study participant400000
Withdrew: Lack of efficacy100000
Withdrew: Adverse event310000
Maintenance Period: Week 16-52
Participant flow — Maintenance Period: Week 16-52
MilestonePlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population)
Started002420020
Completed002200017
Not completed0022003
Withdrew: Withdrawal by study participant0012000
Withdrew: Lack of efficacy004000
Withdrew: Adverse event005000
Withdrew: Lost to follow-up001000
Withdrew: Covid-19 pandemic situation & site restrictions000002
Withdrew: Non- compliance000001

Outcome measures

PrimaryPercentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16

ASAS40 response is defined as relative improvements of at least 40% and absolute improvement of at least 2 units in at least 3 of the 4 following components:1) Patient's Global Assessment of Disease Activity (PGADA) assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most severe pain\], higher score= higher pain intensity, 3) Bath Ankylosing Spondylitis Functional Index (BASFI) assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), each assessed on a scale ranging from 0 \[none / 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity; and no worsening at all in the remaining component.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16
percentage of participantsPlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)
Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 1621.447.727.333.3
Statistical analysis
  • Placebo (up to Week 16) (Global Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.51 · 95% CI 2.00 to 6.16
SecondaryPercentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Subjects at Week 16

ASAS40 response is defined as relative improvements of at least 40% and absolute improvement of at least 2 units in at least 3 of the 4 following components:1) Patient's Global Assessment of Disease Activity (PGADA) assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most severe pain\], higher score= higher pain intensity, 3) Bath Ankylosing Spondylitis Functional Index (BASFI) assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), each assessed on a scale ranging from 0 \[none / 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity; and no worsening at all in the remaining component.

Time frame:
Week 16
Reported as:
Number · percentage of Participants
Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Subjects at Week 16
percentage of ParticipantsPlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)
Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Subjects at Week 1622.946.627.337.5
Statistical analysis
  • Placebo (up to Week 16) (Global Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.08 · 95% CI 1.71 to 5.54
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16

BASDAI is a well-established patient-reported endpoint assessing severity of AS symptoms. It is made of 6 items assessing severity of fatigue, spinal pain, peripheral joint pain \& swelling, enthesitis, \& morning stiffness (both severity and duration). Each question is rated using a numerical rating scale ranging from 0 (none) to 10 (very severe), higher score=higher symptom severity.BASDAI score is calculated by computing mean of questions 5 and 6 \& adding it to sum of questions 1 to 4.This score is then divided by 5.Total BASDAI score ranges from 0=no disease activity to 10=maximal disease activity, higher score indicates higher symptom severity. A negative change reflects improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16
score on a scalePlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16-1.55 ± 0.22-3.07 ± 0.21-2.09 ± 0.564-2.99 ± 0.571
Statistical analysis
  • Placebo (up to Week 16) (Global Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) · ANCOVA · p = <0.001 · Ls mean difference: -1.51 · 95% CI -2.04 to -0.98
  • Placebo (up to Week 16) (China Extension Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) · ANCOVA · p = 0.220 · Ls mean difference: -0.91 · 95% CI -2.42 to 0.61
SecondaryPercentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 16

ASAS20 response is defined as relative improvements of at least 20% and absolute improvement of at least 1 unit in at least 3 of the 4 following components:1) PGADA assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most severe pain\], higher score= higher pain intensity, 3) BASFI assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities, 4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI, each assessed on a scale ranging from 0 \[none / 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity; and no worsening at all in the remaining component.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 16
percentage of participantsPlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)
Percentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 1638.168.854.544.4
Statistical analysis
  • Placebo (up to Week 16) (Global Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.69 · 95% CI 2.17 to 6.26
SecondaryPercentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 16

The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of less than or equal to (\<=) 2 units in each of the 4 following components:1) PGADA assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity,2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most severe pain\], higher score= higher pain intensity, 3) BASFI assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities, and 4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI scale, each assessed on a scale ranging from 0 \[none / 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 16
percentage of participantsPlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 167.125.89.133.3
Statistical analysis
  • Placebo (up to Week 16) (Global Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.52 · 95% CI 2.06 to 9.93
SecondaryPercentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 16

ASDAS-MI is achieved when there is a reduction (improvement) greater or equal to (\>=) 2.0 in ASDAS relative to Baseline. ASDAS is calculated by adding the 5 following components: 1) 0.121 × Neck, back or hip pain (BASDAI Q2), 2) 0.058 × Duration of morning stiffness (BASDAI Q6), 3) 0.110 × Patient's Global Assessment of Disease Activity (PGADA), 4) 0.073 × Peripheral pain/swelling in joints (BASDAI Q3), 5) 0.579 × (natural logarithm of the C-reactive protein (CRP) \[mg/L\] + 1). Q2, Q3 and Q6 from BASDAI and PGADA, are all assessed on a numerical scale from 0 \[none / not active\] to 10 \[very severe / very active\]. There is a minimum score of 0.980 for ASDAS (as a fixed value of 2 is assumed for values of hs-CRP below the lower limit of quantification (LLOQ)), but no defined upper score. Higher ASDAS scores reflect higher disease activity and participants achieving ASDAS-MI are considered to have a major improvement in their disease.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 16
percentage of participantsPlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)
Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 167.127.39.111.1
Statistical analysis
  • Placebo (up to Week 16) (Global Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) · Regression, Logistic · p = <0.001 · Odds ratio (or): 5.43 · 95% CI 2.41 to 12.23
SecondaryPercentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 16

ASAS 5/6 response is defined as achieving at least 20% improvement in 5 of the following 6 components:1) PGADA assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most intense pain\], higher score=higher pain intensity,3) BASFI assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI scale, each assessed on a scale ranging from 0 \[none/ 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity;5) spinal mobility (ie, lateral spinal flexion component of Bath Ankylosing Spondylitis Disease Metrology Index) on a scale ranging from 0 \[no limitation of movement\] to 10 \[very severe limitation of movement\] and 6) high sensitivity C-reactive protein (hs-CRP).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 16
percentage of participantsPlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 1620.645.318.244.4
Statistical analysis
  • Placebo (up to Week 16) (Global Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.31 · 95% CI 1.87 to 5.84
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16

The BASFI is a well-established PRO measure of physical functioning used in AxSpA trials. It assesses participants' level of ability during the past week in conducting 10 physical activities on a scale ranging from 0 \[easy\] to 10 \[impossible\]. The BASFI score is the mean of the 10 item scores and ranges from 0 to 10, with lower scores indicating better physical function. A negative change in BASFI indicates improvement. The higher the negative value the better the improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16
score on a scalePlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16-0.91 ± 0.22-2.39 ± 0.21-0.79 ± 0.340-2.03 ± 0.368
Statistical analysis
  • Placebo (up to Week 16) (Global Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) · ANCOVA · p = <0.001 · Ls mean difference: -1.48 · 95% CI -1.99 to -0.97
  • Placebo (up to Week 16) (China Extension Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) · ANCOVA · p = 0.019 · Ls mean difference: -1.25 · 95% CI -2.26 to -0.24
SecondaryChange From Baseline in Nocturnal Spinal Pain Score Using Numeric Rating Scale (NRS) at Week 16

Nocturnal spinal pain experienced by participants with axial spondyloarthritis (axSpA) was assessed on a numerical rating scale ranging from 0 (no pain) to 10 (most severe pain). A lower score indicates less pain and a negative change represents an improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Nocturnal Spinal Pain Score Using Numeric Rating Scale (NRS) at Week 16
score on a scalePlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)
Change From Baseline in Nocturnal Spinal Pain Score Using Numeric Rating Scale (NRS) at Week 16-1.71 ± 0.27-3.51 ± 0.25-2.41 ± 0.638-3.51 ± 0.658
Statistical analysis
  • Placebo (up to Week 16) (Global Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) · ANCOVA · p = <0.001 · Ls mean difference: -1.80 · 95% CI -2.42 to -1.18
  • Placebo (up to Week 16) (China Extension Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) · ANCOVA · p = 0.199 · Ls mean difference: -1.09 · 95% CI -2.83 to 0.65
SecondaryChange From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16

The Ankylosing Spondylitis Quality of Life (ASQoL) is an 18-item PRO measure developed specifically for measuring health-related quality of life (HRQoL) in participants with ankylosing spondylitis and validated in the full spectrum of axial spondyloarthritis (axSpA). Each item is given a score of 1 for positive responses indicating impaired quality of life, and a score of 0 for negative responses. All item scores are summed to generate the total score ranging from 0 to 18 with a higher score indicating worse HRQoL. A negative change represents an improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16
score on a scalePlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16-2.30 ± 0.43-4.94 ± 0.420.18 ± 0.970-1.66 ± 0.967
Statistical analysis
  • Placebo (up to Week 16) (Global Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) · ANCOVA · p = <0.001 · Ls mean difference: -2.63 · 95% CI -3.66 to -1.61
  • Placebo (up to Week 16) (China Extension Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) · ANCOVA · p = 0.170 · Ls mean difference: -1.84 · 95% CI -4.56 to 0.89
SecondaryChange From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 16

SF-36 is a 36-item HRQoL instrument with recall period of 4 weeks. Items are grouped into 8 domains: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items) and 1 item for Health Transition during last year. PCS and Mental Component Summary (MCS) scores are calculated from 8 domains (excluding Health Transition item). Each of SF-36 derived raw scores range from 0 to 100; higher score = better function. PCS score is calculated from 8 domain scores. It is standardized score ranging from 7.3 to 70.1, with a mean of 50 and SD of 10 in general US population, higher values = better function, and positive change reflects improvement. A PCS score mean below 47 indicates impaired physical functioning. Individual respondent's score that falls outside T-score range of 45 to 55 are outside average general US population range.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · T-score
Change From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 16
T-scorePlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)
Change From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 165.36 ± 0.799.32 ± 0.76-3.52 ± 2.4623.75 ± 2.364
Statistical analysis
  • Placebo (up to Week 16) (Global Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) · ANCOVA · p = <0.001 · Ls mean difference: 3.96 · 95% CI 2.08 to 5.83
  • Placebo (up to Week 16) (China Extension Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) · ANCOVA · p = 0.035 · Ls mean difference: 7.27 · 95% CI 0.60 to 13.95
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16

The BASMI characterizes the spinal mobility of participants with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis. It is a disease-specific measure consisting of 5 clinical measures to reflect participant axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 was calculated for each item based on the measurement. The mean of the 5 scores provides the total BASMI score (ranging from 0 to 10). The higher the BASMI score, the more severe the participant's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value, the better the improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16
score on a scalePlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)
Change From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16-0.11 ± 0.08-0.44 ± 0.080.12 ± 0.211-0.38 ± 0.232
Statistical analysis
  • Placebo (up to Week 16) (Global Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) · ANCOVA · p = <0.001 · Ls mean difference: -0.33 · 95% CI -0.52 to -0.14
  • Placebo (up to Week 16) (China Extension Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) · ANCOVA · p = 0.086 · Ls mean difference: -0.50 · 95% CI -1.07 to 0.07
SecondaryChange From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16

The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score reflects higher severity and a negative change represents an improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16
score on a scalePlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)
Change From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16-1.11 ± 0.38-2.16 ± 0.37-1.35 ± 0.692-1.80 ± 0.871
Statistical analysis
  • Placebo (up to Week 16) (Global Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) · ANCOVA · p = =0.013 · Ls mean difference: -1.06 · 95% CI -1.88 to -0.23
SecondaryPercentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline

The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. Enthesitis free state is defined as having a MASES score of 0. A higher score reflects higher severity and a negative change represents an improvement.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline
percentage of participantsPlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)
Percentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline23.951.160.066.7
Statistical analysis
  • Placebo (up to Week 16) (Global Population) vs Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.49 · 95% CI 1.84 to 6.62
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety follow up (SFU)). TEAEs were analyzed and have been reported separately for Double-Blind Treatment Period (Safety set),Maintenance Period (MP) (Maintenance Set) and Overall Period (Safety set) which includes all participants who received BKZ 160 mg Q4W during the study. The overall period arm reports repeated TEAEs from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, Maintenance Period (MP) included AEs of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.

Time frame:
From Baseline (Day 1) until Safety-Follow-Up (up to Week 68) (Week 48 last IMP intake + 20 weeks SFU)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
percentage of participantsPlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population)Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population)Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (China Population)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study56.362.567.875.072.710080.090.0
SecondaryPercentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study

A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in 1) Death, 2) Life-threatening (Life-threatening does not include a reaction that might have caused death had it occurred in a more severe form.), 3) Significant or persistent disability/incapacity, 4) Congenital anomaly/birth defect (including that occurring in a fetus), 5) Important medical event that, based upon appropriate medical judgment, may jeopardize the participant or participant may require medical or surgical intervention to prevent any of the above, 6) Initial inpatient hospitalization or prolongation of hospitalization. The overall period arm reports repeated SAEs from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, MP included SAEs of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.

Time frame:
From Baseline (Day 1) until Safety Follow-Up (up to Week 68)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study
percentage of participantsPlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population)Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population)Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (China Population)
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study0.803.73.70015.015.0
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study

TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). The overall period arm reports repeated events from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, MP included events of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.

Time frame:
From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study
percentage of participantsPlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population)Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population)Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (China Population)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study4.01.62.53.30000

Adverse events

Collected over From Baseline (Day 1) until Safety Follow-Up (up to Week 68). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (up to Week 16) (Global Population)0/126 (0%)1/126 (0.8%)30/126 (23.8%)
Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)0/128 (0%)0/128 (0%)40/128 (31.3%)
Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population)0/242 (0%)9/242 (3.7%)94/242 (38.8%)
Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (Global Population)0/244 (0%)9/244 (3.7%)114/244 (46.7%)
Placebo (up to Week 16) (China Extension Population)0/11 (0%)0/11 (0%)8/11 (72.7%)
Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)0/9 (0%)0/9 (0%)9/9 (100%)
BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population)0/20 (0%)3/20 (15%)13/20 (65%)
Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (China Population)0/20 (0%)3/20 (15%)16/20 (80%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population)Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population)Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (China Population)
AppendicitisInfections and infestations0/1260/1282/2422/2440/110/91/201/20
Cervical dysplasiaReproductive system and breast disorders0/1260/1280/2420/2440/110/91/201/20
Abortion inducedReproductive system and breast disorders0/1260/1280/2420/2440/110/91/201/20
Abdominal adhesionsGastrointestinal disorders1/1260/1280/2420/2440/110/90/200/20
Deafness unilateralEar and labyrinth disorders0/1260/1281/2421/2440/110/90/200/20
Tonsillitis bacterialInfections and infestations0/1260/1281/2421/2440/110/90/200/20
ErysipelasInfections and infestations0/1260/1281/2421/2440/110/90/200/20
OsteoarthritisMusculoskeletal and connective tissue disorders0/1260/1281/2421/2440/110/90/200/20
Clear cell renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1260/1281/2421/2440/110/90/200/20
Intentional self-injuryPsychiatric disorders0/1260/1281/2421/2440/110/90/200/20
Most frequent other events
Showing 10 of 35
Most frequent other events
EventPlacebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population)Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population)Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (China Population)
Upper respiratory tract infectionInfections and infestations10/1269/12815/24223/2443/111/93/204/20
Liver function test abnormalInvestigations0/1260/1281/2421/2440/112/91/203/20
Corona virus infectionInfections and infestations1/1261/12817/24217/2440/110/94/204/20
Injection site painGeneral disorders2/1262/1283/2425/2442/110/90/200/20
NasopharyngitisInfections and infestations6/12613/12818/24230/2441/110/90/200/20
ThrombocytopeniaBlood and lymphatic system disorders0/1262/1281/2423/2440/111/91/201/20
Vision blurredEye disorders0/1260/1280/2420/2440/111/90/201/20
DiarrhoeaGastrointestinal disorders2/1263/1286/2429/2440/111/90/201/20
GastritisGastrointestinal disorders1/1260/1280/2420/2440/111/90/201/20
Abdominal painGastrointestinal disorders1/1260/1287/2427/2440/111/90/201/20

Baseline characteristics

Baseline Characteristics refer to the Randomized Set which consisted of all randomized study participants. AS0010 China Extension Participants refer to an additional randomized set recruited in China after the closure of the global study recruitment.

Age, Customized
Age, Customized(Participants)Placebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)Total
18 - <65123125119268
65 - <8533006
>= 8500000
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)Total
Female615572125
Male657347149
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)Total
Asian131511948
Black12003
White11010900219
Other/Mixed11002
Missing11002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo (up to Week 16) (Global Population)Bimekizumab 160 mg Q4W (up to Week 16) (Global Population)Placebo (up to Week 16) (China Extension Population)Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population)Total
Hispanic or Latino32005
Not Hispanic or Latino122125119267
Missing11002
08

Study locations

83 sites
  • As0010 50131
    Mesa, Arizona 85210, United States
  • As0010 50052
    Phoenix, Arizona 85032, United States
  • As0010 50062
    Sun City, Arizona 85351, United States
  • As0010 50060
    Upland, California 91786, United States
  • As0010 50059
    Ormond Beach, Florida 32174, United States
  • As0010 50056
    Sarasota, Florida 34239, United States
  • As0010 50015
    Hagerstown, Maryland 21740, United States
  • As0010 50016
    St Louis, Missouri 63141, United States
  • As0010 50055
    Portland, Oregon 97239-3011, United States
  • As0010 50020
    Duncansville, Pennsylvania 16635, United States
  • As0010 50012
    Memphis, Tennessee 38119-5214, United States
  • As0010 50057
    Dallas, Texas 75231, United States
  • As0010 50036
    Mesquite, Texas 75150, United States
  • As0010 50061
    Spokane, Washington 99204, United States
  • As0010 40004
    Brussels, Belgium
  • As0010 40003
    Genk, Belgium
  • As0010 40001
    Ghent, Belgium
  • As0010 40002
    Merksem, Belgium
  • As0010 40006
    Plovdiv, Bulgaria
  • As0010 40007
    Plovdiv, Bulgaria
  • As0010 40005
    Sofia, Bulgaria
  • As0010 40008
    Sofia, Bulgaria
  • As0010 20040
    Beijing, China
  • As0010 20021
    Chengdu, China
  • As0010 20019
    Guangzhou, China
  • As0010 20034
    Hefei, China
  • As0010 20024
    Nanjing, China
  • As0010 20018
    Shanghai, China
  • As0010 20020
    Shanghai, China
  • As0010 20026
    Shanghai, China
  • As0010 20025
    Wenzhou, China
  • As0010 40011
    Brno, Czechia
  • As0010 40009
    Pardubice, Czechia
  • As0010 40013
    Prague, Czechia
  • As0010 40014
    Prague, Czechia
  • As0010 40015
    Prague, Czechia
  • As0010 40016
    Prague, Czechia
  • As0010 40010
    Uherské Hradiště, Czechia
  • As0010 40012
    Zlín, Czechia
  • As0010 40018
    Boulogne-Billancourt, France
  • As0010 40022
    Limoges, France
  • As0010 40025
    Berlin, Germany
  • As0010 40029
    Hamburg, Germany
  • As0010 40024
    Hanover, Germany
  • As0010 40027
    Herne, Germany
  • As0010 40078
    Leipzig, Germany
  • As0010 40026
    Ratingen, Germany
  • As0010 40032
    Debrecen, Hungary
  • As0010 40031
    Szeged, Hungary
  • As0010 40033
    Székesfehérvár, Hungary
  • As0010 40080
    Szombathely, Hungary
  • As0010 20030
    Chūōku, Japan
  • As0010 20039
    Iruma-gun, Japan
  • As0010 20036
    Kawachi-Nagano, Japan
  • As0010 20045
    Kita-gun, Japan
  • As0010 20065
    Kitakyushu, Japan
  • As0010 20038
    Nankoku-shi, Japan
  • As0010 20037
    Osaka, Japan
  • As0010 20084
    Saga, Japan
  • As0010 20048
    Saitama, Japan
  • As0010 20031
    Sapporo, Japan
  • As0010 20035
    Tokyo, Japan
  • As0010 40038
    Elblag, Poland
  • As0010 40042
    Krakow, Poland
  • As0010 40037
    Lublin, Poland
  • As0010 40044
    Poznan, Poland
  • As0010 40040
    Torun, Poland
  • As0010 40041
    Warsaw, Poland
  • As0010 40039
    Wroclaw, Poland
  • As0010 40043
    Wroclaw, Poland
  • As0010 40045
    A Coruña, Spain
  • As0010 40046
    Córdoba, Spain
  • As0010 40047
    Madrid, Spain
  • As0010 40048
    Santiago de Compostela, Spain
  • As0010 40049
    Seville, Spain
  • As0010 40052
    Ankara, Turkey (Türkiye)
  • As0010 40053
    Ankara, Turkey (Türkiye)
  • As0010 40050
    Istanbul, Turkey (Türkiye)
  • As0010 40051
    Izmir, Turkey (Türkiye)
  • As0010 40057
    Edinburgh, United Kingdom
  • As0010 40056
    Leeds, United Kingdom
  • As0010 40054
    London, United Kingdom
  • As0010 40055
    Norwich, United Kingdom
09

References and documents

Publications

  • van der Heijde D, Deodhar A, Baraliakos X, Brown MA, Dobashi H, Dougados M, Elewaut D, Ellis AM, Fleurinck C, Gaffney K, Gensler LS, Haroon N, Magrey M, Maksymowych WP, Marten A, Massow U, Oortgiesen M, Poddubnyy D, Rudwaleit M, Shepherd-Smith J, Tomita T, Van den Bosch F, Vaux T, Xu H. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023 Apr;82(4):515-526. doi: 10.1136/ard-2022-223595. Epub 2023 Jan 17. PubMed 36649967 ↗
  • Navarro-Compan V, Ramiro S, Deodhar A, Mease PJ, Rudwaleit M, de la Loge C, Fleurinck C, Taieb V, Morup MF, Massow U, Kay J, Magrey M. Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD Open. 2024 Apr 10;10(2):e004040. doi: 10.1136/rmdopen-2023-004040. PubMed 38599650 ↗
  • Dubreuil M, Navarro-Compan V, Boonen A, Gaffney K, Gensler LS, de la Loge C, Vaux T, Fleurinck C, Massow U, Taieb V, Morup MF, Deodhar A, Rudwaleit M. Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies. RMD Open. 2024 Jun 4;10(2):e004202. doi: 10.1136/rmdopen-2024-004202. PubMed 38834351 ↗
  • Cella D, de la Loge C, Fofana F, Guo S, Ellis A, Fleurinck C, Massow U, Dougados M, Navarro-Compan V, Walsh JA. The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretation. J Patient Rep Outcomes. 2024 Aug 12;8(1):92. doi: 10.1186/s41687-024-00769-x. PubMed 39133438 ↗
  • Ramiro S, Poddubnyy D, Mease PJ, Lopez-Medina C, Kim M, Massow U, Taieb V, Kragstrup TW, McGonagle D. Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis. RMD Open. 2025 Oct 22;11(4):e005969. doi: 10.1136/rmdopen-2025-005969. PubMed 41125403 ↗
  • Nikiphorou E, Tillett W, Deodhar A, Dubreuil M, Gossec L, Hwang M, Lubrano E, Machado PM, Rudwaleit M, de Wit M, Kavanagh S, de la Loge C, Ink B, Lambert J, Morup M, Boonen A, Walsh J. Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis. J Rheumatol. 2026 Aug 1:jrheum.2026-0104. doi: 10.3899/jrheum.2026-0104. Online ahead of print. PubMed 42386286 ↗
  • Rudwaleit M, Ramiro S, Poddubnyy D, Magrey M, van der Horst-Bruinsma IE, Deodhar A, Taieb V, Kavanagh S, de Peyrecave N, Gensler LS. Bimekizumab efficacy in male and female patients with axial spondyloarthritis: 52-week results from the Phase 3 BE MOBILE rials. Rheumatology (Oxford). 2026 Aug 14:keag425. doi: 10.1093/rheumatology/keag425. Online ahead of print. PubMed 42605056 ↗
  • Baraliakos X, Deodhar A, van der Heijde D, Van den Bosch F, Magrey M, Maksymowych WP, Tomita T, Xu H, Coarse J, Prajapati C, Manente M, Marten A, Gensler LS. Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results From 2 Phase III Studies. J Rheumatol. 2026 Aug 1:jrheum.2026-0113. doi: 10.3899/jrheum.2026-0113. Online ahead of print. PubMed 42297437 ↗
  • Navarro-Compan V, Kiltz U, Mease PJ, Dubreuil M, Gaffney K, Deodhar A, de la Loge C, Prajapati C, Kavanagh S, Marzo-Ortega H. Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension. RMD Open. 2026 May 13;12(2):e006670. doi: 10.1136/rmdopen-2025-006670. PubMed 42128532 ↗
  • Mease PJ, Merola JF, Magrey M, Nash P, Poddubnyy D, Lebwohl M, Bajracharya R, Ink B, Marten A, Manente M, Peterson L, White K, Gensler LS. Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies. RMD Open. 2026 Mar 10;12(1):e006174. doi: 10.1136/rmdopen-2025-006174. PubMed 41807031 ↗
  • Marzo-Ortega H, Navarro-Compan V, Dubreuil M, Mease PJ, Magrey M, Rudwaleit M, D'Agostino MA, Gaffney K, Kay J, de la Loge C, Massow U, Taieb V, Vaux T, Deodhar A. Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies. RMD Open. 2025 Nov 28;11(4):e006013. doi: 10.1136/rmdopen-2025-006013. PubMed 41314667 ↗
  • Mease PJ, Gensler LS, Orbai AM, Warren RB, Bajracharya R, Ink B, Marten A, Massow U, Shende V, Manente M, Peterson L, White K, Landewe R, Poddubnyy D. Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies. RMD Open. 2025 Apr 6;11(2):e005026. doi: 10.1136/rmdopen-2024-005026. PubMed 40194794 ↗
  • Navarro-Compan V, Rudwaleit M, Dubreuil M, Magrey M, Marzo-Ortega H, Mease PJ, Walsh JA, Dougados M, de la Loge C, Fleurinck C, Massow U, Vaux T, Taieb V, Deodhar A. Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies. J Rheumatol. 2025 Jan 1;52(1):23-32. doi: 10.3899/jrheum.2024-0223. PubMed 39406403 ↗
  • Baraliakos X, Deodhar A, van der Heijde D, Magrey M, Maksymowych WP, Tomita T, Xu H, Massow U, Fleurinck C, Ellis AM, Vaux T, Shepherd-Smith J, Marten A, Gensler LS. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Ann Rheum Dis. 2024 Jan 11;83(2):199-213. doi: 10.1136/ard-2023-224803. PubMed 37793792 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Jun 2022, 38 months.

Results were first posted in Nov 2024, 2 years 4 months after primary completion. A results delay was requested in Jun 2023.

Of 20 phase 3 interventional studies under Axial Spondyloarthritis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 39. This study's 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2019
First posted
Apr 26, 2019
StartActual
Apr 25, 2019
Primary completionActual
Jun 29, 2022
CompletionActual
Apr 17, 2023
Results delay requested
Jun 28, 2023
Results first posted
Nov 13, 2024
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42605056 ↗
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42605056 ↗
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03928704
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Apr 26, 2019
Start date
Apr 25, 2019
Primary completion
Jun 29, 2022
Completion
Apr 17, 2023
Results posted
Nov 13, 2024
Last update
Sep 25, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion